Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Cash from Investing Activities (2019 - 2025)

Historic Cash from Investing Activities for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $4.5 million.

  • BridgeBio Pharma's Cash from Investing Activities fell 8832.21% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.4 million, marking a year-over-year decrease of 12090.63%. This contributed to the annual value of $60.8 million for FY2024, which is 1248.87% up from last year.
  • BridgeBio Pharma's Cash from Investing Activities amounted to $4.5 million in Q3 2025, which was down 8832.21% from -$13.0 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Cash from Investing Activities ranged from a high of $149.7 million in Q2 2022 and a low of -$282.1 million during Q1 2021
  • Over the past 5 years, BridgeBio Pharma's median Cash from Investing Activities value was $12.3 million (recorded in 2023), while the average stood at $18.8 million.
  • As far as peak fluctuations go, BridgeBio Pharma's Cash from Investing Activities skyrocketed by 3258602.62% in 2022, and later crashed by 480454.55% in 2024.
  • Quarter analysis of 5 years shows BridgeBio Pharma's Cash from Investing Activities stood at $21.8 million in 2021, then dropped by 17.59% to $18.0 million in 2022, then crashed by 100.37% to -$66000.0 in 2023, then tumbled by 4804.55% to -$3.2 million in 2024, then surged by 237.91% to $4.5 million in 2025.
  • Its Cash from Investing Activities was $4.5 million in Q3 2025, compared to -$13.0 million in Q2 2025 and -$1.6 million in Q1 2025.